-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Enlivex Therapeutics Ltd. annual/quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2016 to 2023.
- Enlivex Therapeutics Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2022 was -$9.91M, a 841% decline year-over-year.
- Enlivex Therapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$29.1M, a 6.41% increase from 2022.
- Enlivex Therapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$31.1M, a 117% decline from 2021.
- Enlivex Therapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$14.3M, a 50.2% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)